
apr pm et
summari largest retail drug chain term revenu compani oper
drug store throughout puerto rico
price-to-earnings oper ep
risk assess reflect compani strong
market share posit rel stabl retail
drug industri partli off-set growth non-tradit
competitor potenti advers legisl
jun ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
see sale grow fy aug
reflect acquisit nearli rite
aid store compstore sale
like grow fy reflect
gain rise demand age
popul partial off-set shift product
non-pharmaci sale declin focus
margin expans competit
environ rather grow volum
despit benefit expand beauti
ebitda margin like narrow
fy fy increas
drug reimburs pressur cost
relat inclus rite aid store
partial off-set benefit cost cut
improv purchas favor
million cost cut anoth
million synergi acquisit
store end calendar year
share repurchas per share
benefit lower tax rate look fy
oper ep rise oper
ep fy exclud one-tim
item period
compani complet acquisit
store march
scale believ import
help improv drug purchas power
believ deal estim ev/ebitda
opportun under-perform
due failur due ftc concern
complet previous agreed-upon deal
acquir billion
risk recommend target price
follow integr recent acquisit
higher-than-expect competit peer
retail format
target price reflect
price-to-earnings near mid-point
five-year trade rang
appli fy ep estim
see valuat pressur intens drug
competit potenti entri new
competitor partial off-set benefit see
expect market share gain
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview one largest drug store chain world
base sale store count compani founder charl rudolph walgreen sr purchas
one busiest drug store chicago south side transform construct ice cream
fountain featur brand ice cream ice cream fountain forerunn
famou walgreen soda fountain becam main attract custom
peopl line buy product wag invent earli milkshak
compani launch loyalti program balanc reward septemb million
member august million august
market profil walgreen oper one largest drug store chain world base sale
gener billion sale fiscal year aug compani fill million
million adjust equival prescript fiscal year
million fiscal year account retail prescript drug market revenu
medicaid repres us pharmaci divis sale fiscal year medicar part
plan contribut us pharmaci sale fiscal year compani also one
largest oper drug store unit basi oper locat state
district columbia puerto rico guam
impact major develop octob compani agre acquir rite aid corpor
oper drug store state district columbia billion cash per
share follow regulatori concern compani reach new agreement acquir
store receiv regulatori approv septemb complet acquisit
store march expect achiev million annual synergi within four year
close deal anoth million cost save end fiscal year think
achiev
septemb compani began new brand gener drug distribut agreement
one north america largest pharmaceut servic compani may
wag extend agreement addit three year august compani
own outstand share elect one member board director august
acquir addit million share open market design
second member abc board director
august compani acquir interest allianc boot lead intern pharmaci
store oper pharmaci wholesal drug distributor suppli
countri billion cash stock august walgreen exercis option
acquir remain interest allianc boot gbp billion cash million share
wag stock deal complet decemb
walgreen achiev goal billion allianc boot annual synergi third quarter fiscal
year compani think signific short- long-term synergi opportun
gener procur save revenu gener procur save includ prescript
drug counter front-end non-pharmaci purchas indirect spend cost save revenu
opportun includ introduc allianc boot product brand drug store oper walgreen
addit revenu synergi may gener share best practic particularli
pharmaci oper health well servic logist
januari pharmaci benefit manag pbm contract walgreen
script esrx expir follow expir contract walgreen longer part
script network therefor longer accept prescript reimburs express script
custom cover health plan administ express script result custom
sought altern mean fill prescript impass impact approxim million
prescript previous fill walgreen cover health plan administ
script end march walgreen retain million prescript
previous cover contract juli compani reach new multi-year pharmaci
network agreement express script wag becam part express script network
pharmaci septemb
april compani acquir new york-bas drug store chain duan read affili oak
hill capit partner total enterpris valu billion cash acquisit includ drug
store two distribut center acquisit provid compani lead market share posit
new york citi largest drug store market
financi trend august board author share repurchas program billion
stock expir august repurchas million share fy cost
million anoth million share million fiscal year compani complet
billion share repurchas program fiscal year ad anoth billion author
octob expect maintain dividend pay-out ratio
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
base index
five-year market price perform apr
prescript front-end sale servic
expand
year date decemb
compar rise
industri index declin
compar increas
think under-perform
reimburs pressur slow in-stor
traffic trend due increas competit
despit increas demand favor
demograph age babi boomer
expand health care coverag
note sector sub-industri inform base
past perform indic futur perform
reli upon
neutral fundament outlook
drug retail sub-industri next month
see sale continu benefit
increas demand age babi boomer
see margin benefit increas gener drug
purchas power improv sale leverag
howev see margin expans limit
intens drug reimburs pressur
increas competit non-tradit
compani within retail drug industri
well posit view benefit
increas prescript drug usag
develop privat loyalti card
program prescript volum like rise
age babi boomer nearli
util prescript drug addit
reflect conveni locat close
consum home retail drugstor better
posit take market share
non-tradit competitor expans
loyalti card program like help support
increas basket size traffic reflect
person shop experi
custom also loyalti program like
help support retail margin due improv
market promot spend effici
expect near-term advers
impact potenti chang health care
legisl long-term demand would
restrict peopl lose health care
coverag also expect prescript revenu
growth somewhat limit next
month due convers brand drug
lower-pr gener drug near-term peak
benefit sale gener drug
occur believ gener
drug sale acceler slightli
also see in-stor health clinic offer
increasingli help drive store traffic
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
industri drug reimburs pressur potenti entri new competitor
set fy ep aug-q ep vs
estim store sale growth estim hurt
reduc promot transfer acquir store begun expect
complet spring synergi million within year /joseph
et cfra keep buy opinion share walgreen boot
allianc lift target price-to-earnings
averag calendar ep estim
see discount warrant drug reimburs competit
lift fy aug ep estim expect share
buyback agre buy store
billion cash pend approv pay million end prior deal
view deal favor estim ev/ebitda expect scale
turnaround opportun may-q ep vs estim
et cfra keep buy opinion share walgreen boot
allianc lift target price-to-earnings
averag calendar ep estim
believ discount warrant due intens retail competit
pressur reduc drug reimburs rate feb-q adjust ep
vs estim retail compar store sale
declin expect reflect intens competit food
deflat despit growth beauti pharmaci volum growth
stronger expect reflect share gain strateg partnership /j
et capit iq keep buy opinion share
walgreen boot allianc inc cut
target price-to-earnings averag fy
aug ep estim see valuat pressur drug
reimburs pressur fy estim exclud estim accret
expect acquisit expect
receiv ftc approv set fy ep estim nov-q
adjust ep vs estim compar
store sale growth miss estim see demand
strengthen feb-q flu activ acceler /j agnes
analyst research note compani news
keep target price ev/ebitda
line peer assum complet rad merger
albertson end calendar keep fy feb ep
estim initi fy ep feb-q adjust loss per
share vs loss wider estim reflect
recent asset sale store sale declin line
expect hurt exclus health plan pharmaci network
intens non-pharmaci competit posit view stabil drug
reimburs rate feb-q sourc signific margin
pressur recent year expect margin benefit reduc gener drug
purchas cost compani leverag new sourc relationship
follow complet sale
store march /joseph agnes
et cfra keep buy opinion share walgreen boot
allianc trim target price-to-earnings
lower end rang fy aug ep estim
see valuat hurt intens drug reimburs
pressur partial off-set benefit increas scale lift fy
ep estim feb-q ep vs
estim compar store sale growth estim
benefit pharmaci market share gain see non-pharmaci sale
pressur priorit margin expans volum growth /joseph
et cfra keep hold recommend share
amerisourcebergen corpor lift target
ev/ebitda near high end rang
see valuat support made
take-over approach accord wall street journal
surpris decis seek acquir remain
alreadi although talk reportedli earli stage
combin make strateg sens us greater scale would help off-set
drug reimburs pressur perman secur relationship
key drug supplier /joseph agnes
et cfra keep buy recommend share walgreen
boot allianc rais target price
appli price-to-earnings near mid-point
rang fy august ep estim see
valuat benefit strong cough cold flu season hurt continu
drug reimburs pressur increas fy ep estim
expect tax reform boost fy ep see addit
near-term ep benefit increas traffic store sever flu season
 drive increas sale pharmaci wider margin non-pharmaci
et cfra keep buy opinion share walgreen boot
allianc inc keep target price
price-to-earnings lower end rang fy august ep
estim see valuat hurt lower drug
reimburs rate potenti entri new competitor increas
fy ep estim nov-q adjust ep vs
estim declin share count compar
store sale growth estim support
volum gain medicar part strateg partnership see
allianc inc lower target price
price-to-earnings lower end rang fy aug
ep estim expect valuat pressur on-going
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
